share_log

华东医药(000963.SZ):目前在新西兰的Ⅰb/Ⅱa临床中有观察到肝脏脂肪影像学初步疗效信号

Huadong Pharmaceutical (000963.SZ): Currently, initial efficacy signals of liver fat imaging have been observed in the Ib/IIA clinical trial in New Zealand

Gelonghui Finance ·  Apr 19 05:17

Gelonghui, April 19丨Huadong Pharmaceutical (000963.SZ) held a 2023 annual performance exchange meeting on April 18, 2024 to discuss “the future of the company's three-target GLP-1 products in NASH and weight loss?” The company replied that DR10624 is a three-target agonist targeting FGF21R/GCGR/GLP-1R, and the company will prioritize clinical research on metabolic diseases such as hypertriglyceridemia and NASH in the future. Currently, initial efficacy signals of liver fat imaging have been observed in the Ib/IIa clinical trial in New Zealand, which is expected to bring new treatment options to patients with metabolic diseases in the future.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment